Multiple Sclerosis Clinical Trial
Official title:
An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Verified date | May 2018 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study seeks to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of ABT-555 in participants with relapsing forms of multiple sclerosis (RFMS).
Status | Completed |
Enrollment | 20 |
Est. completion date | April 20, 2018 |
Est. primary completion date | April 20, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Currently receiving one of the following MS medications for at least 3 months: beta-interferon (any formulation including the pegylated form), glatiramer acetate (Copaxone®, others), teriflunomide (Aubagio®), fingolimod (Gilenya®), or dimethyl fumarate (Tecfidera®); OR - Has not been treated with an MS immunotherapy for the past 6 months (12 months if they previously received cyclophosphamide or alemtuzumab); OR - Treatment naïve with established MS diagnosis per criteria by a neurologist. - Diagnosis of relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) according to revised McDonald criteria - Baseline Expanded Disability Status Scale (EDSS) between 0 and 6.0, inclusive. - Brain MRI scan at Screening that did not show evidence of overt vascular lesions, masses, mass effect or other abnormalities other than those compatible with MS, which would preclude the participant from undergoing a lumbar puncture/spinal tap for CSF collection Exclusion Criteria: - Diagnosis of primary progressive MS. - Anticipated maintenance immunomodulator change, either agent or dose - An MS relapse that occurred within the 30 days prior to randomization AND/OR the participant has not stabilized from a previous relapse prior to randomization - Participants for whom MRI is contraindicated - Participants who have claustrophobia that cannot be medically managed or are unable to lie still for 1 hour or more for the imaging procedures - Findings on brain MRI scan indicating any clinically significant brain abnormality other than MS - Contraindication for lumbar puncture |
Country | Name | City | State |
---|---|---|---|
United States | Integrated Neurology Services | Alexandria | Virginia |
United States | Parexel International | Baltimore | Maryland |
United States | Duke Univ Med Ctr | Durham | North Carolina |
United States | MIND | Farmington Hills | Michigan |
United States | Clinical Trial Network | Houston | Texas |
United States | Tri-State Mountain Neurology | Johnson City | Tennessee |
United States | Rowe Neurology Institute | Lenexa | Kansas |
United States | Compass Research LLC | Orlando | Florida |
Lead Sponsor | Collaborator |
---|---|
AbbVie |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number and percentage of participants reporting adverse events | Throughout study from Day 1 to Day 176 | ||
Primary | Concentration of anti-drug antibody (ADA) titers of ABT-555 | Day 1 to Day 176 | ||
Primary | Time to Maximum observed plasma concentration (Tmax) of ABT-555 | Day 1 to Day 176 | ||
Primary | Maximum observed plasma concentration (Cmax) of ABT-555 | Day 1 to Day 176 | ||
Primary | Area under the concentration curve (AUC) of ABT-555 | Day 1 to Day 176 | ||
Secondary | Percentage of participants who experience relapse and disability progression | Throughout the study to Day 176 | ||
Secondary | Lesion volume of new, newly enlarging T2 hyperintense lesions | Throughout study from Day 0 to Day 113 | ||
Secondary | Number of new, newly-enlarging T2 hyperintense lesions | Throughout study from Day 0 to Day 113 | ||
Secondary | Total number of new Gadolinium-enhancing T1 lesions | Throughout study from Day 0 to Day 113 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |